Skip to main content
SpringerLink
Log in

Peripheral Neuropathy

  • Protocol
  • First Online:
Clinical Trials in Neurology

Part of the book series: Neuromethods ((NM,volume 138))

  • 681 Accesses

Abstract

Peripheral neuropathy is a condition that involves different symptoms and can be caused by different pathologies, especially diabetes mellitus. Due to its high incidence and the great number of challenges faced by researchers in this field, this chapter provides an extensive discussion of the 100 most cited clinical trials between 2005 and 2015. A systematic review was performed, based on the CONSORT guidelines, by analyzing Web of Science database as to improve the planning of future trials and addressing the main aspects involved with Peripheral Neuropathy clinical trials.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Protocol
USD 49.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 249.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Vinik A, Park T, Stansberry K (2000) Diabetic neuropathies. Diabetologia 43:957–973

    Article  CAS  PubMed  Google Scholar 

  2. Carozzi VA, Canta A, Chiorazzi A (2015) Chemotherapy-induced peripheral neuropathy: what do we know about mechanisms? Neurosci Lett 596:90–107. https://doi.org/10.1016/j.neulet.2014.10.014

    Article  PubMed  CAS  Google Scholar 

  3. Driessen CML, de Kleine-Bolt KME, Vingerhoets AJ et al (2012) Assessing the impact of chemotherapy-induced peripheral neurotoxicity on the quality of life of cancer patients: the introduction of a new measure. Support Care Cancer 20:877–881. https://doi.org/10.1007/s00520-011-1336-0

    Article  PubMed  CAS  Google Scholar 

  4. Seretny M, Currie GL, Sena ES et al (2014) Incidence, prevalence, and predictors of chemotherapy-induced peripheral neuropathy: a systematic review and meta-analysis. Pain 155:2461–2470. https://doi.org/10.1016/j.pain.2014.09.020

    Article  PubMed  Google Scholar 

  5. Cavaletti G, Marmiroli P (2010) Chemotherapy-induced peripheral neurotoxicity. Nat Rev Neurol 3:535–546. https://doi.org/10.1517/14740338.3.6.535

    Article  CAS  Google Scholar 

  6. Argyriou AA, Chroni E, Koutras A et al (2006) Preventing paclitaxel-induced peripheral neuropathy: a phase II trial of vitamin E supplementation. J Pain Symptom Manage 32(3):237–244. https://doi.org/10.1016/j.jpainsymman.2006.03.013

    Article  PubMed  CAS  Google Scholar 

  7. Kottschade LA, Sloan JA, Mazurczak MA et al (2011) The use of vitamin E for the prevention of chemotherapy-induced peripheral neuropathy: results of a randomized phase III clinical trial. Support Care Cancer 19(11):1769–1777. https://doi.org/10.1007/s00520-010-1018-3

    Article  PubMed  Google Scholar 

  8. Please provide bibliographic details for Ref. 8

    Google Scholar 

  9. Offidani M, Corvatta L, Marconi M et al (2004) Common and rare side-effects of low-dose thalidomide in multiple myeloma: focus on the dose-minimizing peripheral neuropathy. Eur J Haematol 72:403–409. https://doi.org/10.1111/j.1600-0609.2004.00238.x

    Article  PubMed  CAS  Google Scholar 

  10. Razazian M, Bazyiar M, Moradian N et al (2014) Evaluation of the efficacy and safety of pregabalin, venlafaxine, and carbamazepine in patients with painful diabetic peripheral neuropathy. Neuroscienses (Riyadh) 19(3):192–198

    Google Scholar 

  11. Richardson PG, Sonneveld P, Shuster MW et al (2009) Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: impact of a dose-modification guideline. Br J Haematol 144(6):895–903. https://doi.org/10.1111/j.1365-2141.2008.07573.x

    Article  PubMed  CAS  Google Scholar 

  12. Portney LG, Watkins MP (2009) Foundations of clinical research: applications to practice. Pearson/Prentice Hall, Upper Saddle River, NJ

    Google Scholar 

  13. Please provide bibliographic details for Ref. 13

    Google Scholar 

  14. Vinik AL, Shapiro DY, Rauschkolb C et al (2014) A randomized withdrawal, placebo-controlled study evaluating the efficacy and tolerability of tapentadol extended release in patients with chronic painful diabetic peripheral neuropathy. Diabetes Care 37(8):2302–2309. https://doi.org/10.2337/dc13-2291

    Article  PubMed  CAS  Google Scholar 

  15. Raskin P, Huffman C, Toth C et al (2014) Pregabalin in patients with inadequately treated painful diabetic peripheral neuropathy a randomized withdrawal trial. Clin J Pain 30(5):379–390. https://doi.org/10.1097/AJP.0b013e31829ea1a1.

    Article  PubMed  Google Scholar 

  16. Vahdat L, Papadopoulos K, Lange D et al (2001) Reduction of paclitaxel-induced peripheral neuropathy with glutamine. Clin Cancer Res 7(5):1192–1197

    PubMed  CAS  Google Scholar 

  17. Stubblefield MD, Vahdat LT, Balmaceda CM et al (2005) Glutainine as a neuroprotective agent in high-dose paclitaxel-induced peripheral neuropathy: a clinical and electrophysiologic study. Clin Oncol 17:271–276. https://doi.org/10.1016/j.clon.2004.11.014

    Article  CAS  Google Scholar 

  18. Goldblatt EM, Lee W-H (2010) From bench to bedside: the growing use of translational research in cancer medicine. Am J Transl Res 2:1–18

    PubMed  PubMed Central  Google Scholar 

  19. Coriat R, Alexandre J, Nicco C et al (2014) Treatment of oxaliplatin-induced peripheral neuropathy by intravenous mangafodipir. J Clin Invest 124:262–272. https://doi.org/10.1172/JCI68730

    Article  PubMed  CAS  Google Scholar 

  20. Tamimi NA, Ellis P (2009) Drug development: from concept to marketing. Nephron Clin Pract 113:125–131. https://doi.org/10.1159/000232592

    Article  CAS  Google Scholar 

  21. Mielke S, Sparreboom A, Steinberg SM et al (2005) Association of Paclitaxel pharmacokinetics with the development of peripheral neuropathy in patients with advanced cancer. Clin Cancer Res 11:4843–4850. https://doi.org/10.1158/1078-0432.CCR-05-0298

    Article  PubMed  CAS  Google Scholar 

  22. Verstanppen C, Koeppen S, Heimans J et al (2005) Dose-related induced peripheral neuropathy with unexpected off-therapy worsening. Neurology 64:1076–1077

    Article  CAS  Google Scholar 

  23. Thisted RA, Klaff L, Schwartz SL et al (2006) Dextromethorphan and quinidine in adult patients with uncontrolled painful diabetic peripheral neuropathy: a 29-day, multicenter, open-label, dose-escalation study. Clin Ther 28(10):1607–1618

    Article  CAS  PubMed  Google Scholar 

  24. Leon AC, Davis LL, Kraemer HC (2012) Role and interpretation of pilot studies in clinical research. J Psychiatr Res 45:626–629. https://doi.org/10.1016/j.jpsychires.2010.10.008.The

    Article  Google Scholar 

  25. Paice JA, Ferrans CE, Lashley FR et al (2000) Topical capsaicin in the management of HIV-associated peripheral neuropathy. J Pain Symptom Manage 19(1):45–52

    Article  CAS  PubMed  Google Scholar 

  26. Rao RD, Michalak JC, Sloan JA et al (2007) Efficacy of gabapentin in the management of chemotherapy-induced peripheral neuropathy - a phase 3 randomized, double-blind, placebo-controlled, crossover trial (NOOC3). Cancer 110(9):2110–2118

    Article  CAS  PubMed  Google Scholar 

  27. Hotta N, Akanuma Y, Kawamori R et al (2006) Long-term clinical effects of epalrestat, an aldose reductase inhibitor, on diabetic peripheralneuropathy - the 3-year, multicenter, comparative aldose reductase inhibitor-diabetes complications trial. Diabetes Care 29(7):1538–1544

    Article  CAS  PubMed  Google Scholar 

  28. Strempska B, Bilinska M, Weyde W et al (2013) The effect of high-tone external muscle stimulation on symptoms and electrophysiological parameters of uremic peripheral neuropathy. Clin Nephrol 79(Suppl 1):S24–S27

    PubMed  Google Scholar 

  29. Bestard JA, Toth CC (2011) An open-label comparison of nabilone and gabapentin as adjuvant therapy or monotherapy in the management of neuropathic pain in patients with peripheral neuropathy. Pain Pract 11(4):353–368. https://doi.org/10.1111/j.1533-2500.2010.00427.x.

    Article  PubMed  Google Scholar 

  30. Tuttle KR (2015 Apr) Effect of ruboxistaurin on albuminuria and estimated GFR in people with diabetic peripheral neuropathy: results from a randomized trial. Am J Kidney Dis 65(4):634–636

    Article  CAS  PubMed  Google Scholar 

  31. Valensi P (2005 Sep-Oct) A multicenter, double-blind, safety study of QR-333 for the treatment of symptomatic diabeticperipheral neuropathy - a preliminary report. J Diabetes Complications 19(5):247–253

    Article  PubMed  Google Scholar 

  32. Simpson DM, Estanislao L, Brown SJ et al (2008) An open-label pilot study of high-concentration capsaicin patch in painful HIV neuropathy. J Pain Sympton Manage 35(3):299–306

    Article  CAS  Google Scholar 

  33. Cornblath DR, Hoke A (2006) Recent advances in HIV neuropathy. Curr Opin Neurol 19:446–450

    Article  PubMed  Google Scholar 

  34. Verma S, Estanislao L, Simpson D (2005) HIV-associated neuropathic pain: epidemiology, pathophysiology and management. CNS Drugs 19(4):325–334

    Article  PubMed  Google Scholar 

  35. Schifitto G, McDermott MP, McArthur JC, Marder K, Sacktor N, Epstein L et al (2002) Incidence of and risk factors for HIV-associated distal sensory polyneuropathy. Neurology 58:1764–1768

    Article  CAS  PubMed  Google Scholar 

  36. Anastasi JK, Capili B, McMahon DJ, Scully C (2013) Acu/moxa for distal sensory peripheral neuropathy in HIV: a randomized control pilot study. J Assoc Nurses AIDS Care 24:268–275. https://doi.org/10.1016/j.jana.2012.09.006

    Article  PubMed  PubMed Central  Google Scholar 

  37. Slangen R, Schaper NC, Faber CG et al (2014) Spinal cord stimulation and pain relief in painful diabetic peripheral neuropathy: a prospective two-center randomized controlled trial. Diabetes Care 37:3016–3024. https://doi.org/10.2337/dc14-0684

    Article  PubMed  Google Scholar 

  38. Rosenstock J, Tuchman M, Lamoreaux L, Sharma U (2004) Pregabalin for the treatment of painful diabetic peripheral neuropathy: a double-blind, placebo-controlled trial. Pain 110:628–638 PMID:15288403

    Article  CAS  PubMed  Google Scholar 

  39. Raskin P, Huffman C, Toth C et al (2014) Pregabalin in patients with inadequately treated painful diabetic peripheral neuropathy a randomized withdrawal trial. Clin J Pain 30(5):379–390. https://doi.org/10.1097/AJP.0b013e31829ea1a1

    Article  PubMed  Google Scholar 

  40. Richter RW, Portenoy R, Sharma U et al (2005) Relief of painful diabetic peripheral neuropathy with pregabalin: a randomized, placebo-controlled trial. J Pain 6:253–260. https://doi.org/10.1016/j.jpain.2004.12.007

    Article  PubMed  CAS  Google Scholar 

  41. Baron R, Brunnmuller U, Brasser M, May M, Binder A (2008) Efficacy and safety of pregabalin in patients with diabetic peripheral neuropathy or postherpetic neuralgia: open-label, non-comparative, flexible-dose study. Eur J Pain 12(7):850–858

    Article  CAS  PubMed  Google Scholar 

  42. Arezzo JC, Rosenstock J, LaMoreaux L, Pauer L (2008) Efficacy and safety of pregabalin 600 mg/d for treating painful diabetic peripheral neuropathy: a double-blind placebo-controlled trial. BMC Neurol 8:33. https://doi.org/10.1186/1471-2377-8-33

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  43. Satoh J, Yagihashi S, Baba M et al (2011) Efficacy and safety of pregabalin for treating neuropathic pain associated with diabetic peripheral neuropathy: a 14 week, randomized, double-blind, placebo-controlled trial. Diabet Med 28(1):109–116. https://doi.org/10.1111/j.1464-5491.2010.03152 PMID: 21166852

    Article  PubMed  CAS  Google Scholar 

  44. Smith EML, Pang H, Cirrincione C et al (2013) Effect of duloxetine on pain, function, and quality of life among patients with chemotherapy-induced painful peripheral neuropathy: a randomized clinical trial. JAMA Psychiat 309:1359–1367

    CAS  Google Scholar 

  45. Walton MK, Iii JHP, Hobart J et al (2015) Clinical outcome assessments: conceptual foundation—report of the ISPOR clinical outcomes assessment – Emerging good practices for outcomes research task force. Value Health 18:741–752

    Article  PubMed  PubMed Central  Google Scholar 

  46. Ravina B, Cummings J, Mcdermott M, Poole RM (2012) Selecting outcome measures. In: Clinical trials in neurology. Cambridge University Press, Cambridge, pp 69–77

    Chapter  Google Scholar 

  47. Stephens RJ, Hopwood P, Girling DJ, Machin D (1997) Randomized trials with quality of life endpoints: are doctors’ ratings of patients’ physical symptoms interchangeable with patients’ self-ratings? Qual Life Res 6:225–236. https://doi.org/10.1023/A:1026458604826

    Article  PubMed  CAS  Google Scholar 

  48. Nagano H, Sanai H, Muraoka M, Takagi K (2012) Efficacy of lafutidine, a histamine H2-receptor antagonist, for taxane-induced peripheral neuropathy in patients with gynecological malignancies. Gynecol Oncol 127:172–174. https://doi.org/10.1016/j.ygyno.2012.06.029

    Article  PubMed  CAS  Google Scholar 

  49. Atkinson AJJ, Colburn WA, DeGruttola VG et al (2001) Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther 69:89–95. https://doi.org/10.1067/mcp.2001.113989

    Article  Google Scholar 

  50. Schulz KF, Altman DG, Moher D, Group C (2010) Academia and clinic annals of internal medicine CONSORT 2010 statement: updated guidelines for reporting parallel group randomized trials. Ann Intern Med 152:727–732. https://doi.org/10.7326/0003-4819-152-11-201006010-00232

    Article  Google Scholar 

  51. Schulz KF, Grimes DA (2005) Sample size calculations in randomised trials: mandatory and mystical. Lancet 365:1348–1353. https://doi.org/10.1016/S0140-6736(05)61034-3

    Article  PubMed  Google Scholar 

  52. Hotta N, Toyota T, Matsuoka K et al (2001) Clinical efficacy of fidarestat, a novel aldose reductase inhibitor, for diabetic peripheral neuropathy. Diabetes Care 24:1776–1782

    Article  CAS  PubMed  Google Scholar 

  53. Fonseca VA, Lavery LA, Thethi TK et al (2013) Metanx in type 2 diabetes with peripheral neuropathy: a randomized trial. Am J Med 126:141–149. https://doi.org/10.1016/j.amjmed.2012.06.022

    Article  PubMed  CAS  Google Scholar 

  54. Cohen J (1988) Statistical power analysis for the behavioral sciences, 2nd edn. Academic, New York

    Google Scholar 

  55. Schulz KF, Grimes DA (2002) Generation of allocation sequences in randomised trials: chance, not choice. Lancet 359:515–519

    Article  PubMed  Google Scholar 

  56. Vickers AJ (2008) How to randomize. J Soc Integr Oncol 4:194–198

    Article  Google Scholar 

  57. Altman DG, Bland JM (1999) Treatment allocation in controlled trials: why randomise? BMJ 318:1209. https://doi.org/10.1136/bmj.329.7458.168

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  58. Schulz KF, Grimes DA (2002) Allocation concealment in randomised trials: defending against deciphering. Lancet 359:614–618

    Article  PubMed  Google Scholar 

  59. Schulz KF (1995) Subverting randomization in controlled trials. JAMA 274:1456–1458

    Article  CAS  PubMed  Google Scholar 

  60. Schulz KF (2002) The landscape and lexicon of blinding in randomized trials. Ann Intern Med 136:254–259

    Article  PubMed  Google Scholar 

  61. Schulz KF, Grimes DA (2002) Blinding in randomised trials: hiding who got what. Lancet 359:696–700

    Article  PubMed  Google Scholar 

  62. Bang H, Ni L, Davis CE (2004) Assessment of blinding in clinical trials. Control Clin Trials 25:143–156. https://doi.org/10.1016/j.cct.2003.10.016

    Article  PubMed  Google Scholar 

  63. Nicholson LM, Schwirian PM, Groner JA (2015) Recruitment and retention strategies in clinical studies with low-income and minority populations: progress from 2004–2014. Contemp Clin Trials. https://doi.org/10.1016/j.cct.2015.07.008

  64. Thoma A, Farrokhyar F, Mcknight L, Bhandari M (2010) How to optimize patient recruitment. Can J Surg 53:205–210

    PubMed  PubMed Central  Google Scholar 

  65. Robiner WN (2005) Enhancing adherence in clinical research. Contemp Clin Trials 26:59–77. https://doi.org/10.1016/j.cct.2004.11.015

    Article  PubMed  Google Scholar 

  66. Richter RW, Portenoy R, Sharma U et al (2005) Relief of painful diabetic peripheral neuropathy with pregabalin: a randomized, placebo-controlled trial. J Pain 6:253–260. https://doi.org/10.1016/j.jpain.2004.12.007

    Article  PubMed  CAS  Google Scholar 

  67. Lemaster JW, Mueller MJ, Reiber GE et al (2008) Effect of weight-bearing activity on foot ulcer incidence in people with diabetic peripheral neuropathy: feet first randomized controlled trial. Phys Ther 88:1385–1398. https://doi.org/10.2522/ptj.20080019

    Article  PubMed  Google Scholar 

  68. Bailar JC, Mosteller F (1988) Guidelines for reporting in articles for medical journals. Ann Intern Med 108:266–273. https://doi.org/10.7326/0003-4819-108-2-266

    Article  PubMed  Google Scholar 

  69. Dziura JD, Post LA, Zhao Q et al (2013) Strategies for dealing with missing data in clinical trials: from design to analysis. Yale J Biol Med 86:343–358

    PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Laboratory of Neuromodulation, Center of Clinical Research Learning, Spaulding Rehabilitation Hospital, Harvard Medical School, Boston, MA, USA

    Rafaelly Stavale, Felipe Jones, Alejandra Malavera & Felipe Fregni

Authors
  1. Rafaelly Stavale
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Felipe Jones
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Alejandra Malavera
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Felipe Fregni
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Felipe Fregni .

Editor information

Editors and Affiliations

  1. Laboratory of Neuromodulation, Center of Clinical Research Learning, Spaulding Rehabilitation Hospital, Harvard Medical School, Boston, Massachusetts, USA

    Felipe Fregni

Rights and permissions

Reprints and permissions

Copyright information

© 2018 Springer Science+Business Media, LLC, part of Springer Nature

About this protocol

Check for updates. Verify currency and authenticity via CrossMark

Cite this protocol

Stavale, R., Jones, F., Malavera, A., Fregni, F. (2018). Peripheral Neuropathy. In: Fregni, F. (eds) Clinical Trials in Neurology. Neuromethods, vol 138. Humana Press, New York, NY. https://doi.org/10.1007/978-1-4939-7880-9_12

Download citation

  • DOI: https://doi.org/10.1007/978-1-4939-7880-9_12

  • Published:

  • Publisher Name: Humana Press, New York, NY

  • Print ISBN: 978-1-4939-7879-3

  • Online ISBN: 978-1-4939-7880-9

  • eBook Packages: Springer Protocols

Publish with us

Policies and ethics

Search

Navigation